CataX AI Raises RMB 40 Million Seed Round to Reinvent Clinical Development

China's CataX AI has closed a RMB 40 million (USD 6 million) seed round exclusively backed and incubated by Qiming Venture Partners, launching an agent-native model for drug development founded in Shanghai in July 2026. The company targets the clinical-development bottleneck rather than early discovery, using specialised agents to run literature synthesis, document drafting and data handling while clinicians retain decision authority.

Its Clinical-of-One paradigm lets a single clinical lead orchestrate an entire programme, with project knowledge continuously captured and reused across assets. CataX plans to in-license or co-develop preclinical and early-stage candidates to proof-of-concept, betting that agent infrastructure lowers cycle time and cost more decisively than incremental trial-tooling.

The raise reflects investor conviction that AI's next margin of value in pharma lies not in generating molecules but in de-risking and accelerating the expensive, protocol-heavy path from first-in-human studies to registrational evidence.

Daily News
Abbott Pays USD 40mn Upfront for Disco AND-Gated Bispecific Option
2026-11-20
MegaRobo Raises USD 200mn to Scale Physical-World AI Infrastructure
2026-11-20
Novartis Enters ADC Arena With Over USD 2bn OBI Pharma Platform Deal
2026-11-19
Pfizer Licenses Starna's In Vivo CAR-T Platform for Up to USD 2.63bn
2026-11-19
Zelgen's CD3×DLL3 Trispecific Hits Pivotal Endpoint in Relapsed SCLC
2026-11-19
Latest Report
AI- in-BD- Portfolio
Details